A phase I dose-escalation study (NCT03708328) is ongoing to evaluate the safety and preliminary antitumor activity of a PD-1/TIM-3 bispecific antibody (RO7121661) in patients with advanced or metastatic solid tumors, including HNSCC. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.